Clinical Trial Detail

NCT ID NCT02601937
Title A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements yes
Sponsors Epizyme, Inc.
Indications

rhabdoid cancer

myoepithelial carcinoma

myxoid chondrosarcoma

collecting duct carcinoma

epithelioid sarcoma

epithelioid malignant peripheral nerve sheath tumor

synovial sarcoma

Therapies

Tazemetostat

Age Groups: child adult

Additional content available in CKB BOOST